Becton, Dickinson and Company (BD), a Franklin Lakes, New Jersey-based medical technology company, has announced it is investing $100 million to expand capacity for its insulin syringe manufacturing operations at its Holdrege, Nebraska facility. The investment will be used for new technology and manufacturing equipment to expand capacity for BD insulin syringes.

BD began operations in Holdrege in 1966 in a 12,000-square-foot building with 66 associates. Today, the facility has grown to 350,000 square feet with more than 650 associates manufacturing 20 different BD products.

Across Nebraska, BD employs more than 2,500 associates in four manufacturing facilities in Holdrege, Broken Bow, and two in Columbus.

Source: Becton, Dickinson and Company